Eli Lilly and Company (NYSE:LLY) Rating Lowered to Hold at Daiwa America

by · The Cerbat Gem

Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by investment analysts at Daiwa America from a “strong-buy” rating to a “hold” rating in a report issued on Sunday,Zacks.com reports.

LLY has been the topic of a number of other reports. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Cantor Fitzgerald decreased their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. HSBC downgraded Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $950.17.

Get Our Latest Research Report on LLY

Eli Lilly and Company Price Performance

Shares of LLY opened at $698.89 on Friday. The company has a 50 day moving average of $763.06 and a two-hundred day moving average of $793.64. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $972.53. The company has a market cap of $661.47 billion, a price-to-earnings ratio of 45.68, a price-to-earnings-growth ratio of 0.98 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the business earned $3.92 EPS. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

A number of institutional investors and hedge funds have recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its position in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Vanguard Group Inc. boosted its stake in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares in the last quarter. GAMMA Investing LLC raised its position in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP boosted its stake in Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after purchasing an additional 81,587 shares in the last quarter. Finally, Laurel Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also